Compare Carvana Co (CVNA) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Carvana Co vs Neurocrine Biosciences Inc — how do they compare? Carvana Co trades at $72.25 (market cap $79.17B), while Neurocrine Biosciences Inc trades at $152 (market cap $16.46B). The key difference: Carvana Co is far larger — about 4.8× Neurocrine Biosciences Inc's market cap. Which is the better fit depends on your goals.
| CVNA | NBIX | |
|---|---|---|
Market Cap | $79.17B | $16.46B |
Sector | Consumer Cyclical | Health |
52-Week High | $95.69 | $185.50 |
52-Week Low | $56.27 | $123.10 |
Enterprise Value | $81.65B | $16.48B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Carvana (CVNA) trades at $74.20, up 4.73% today, with strong recent earnings beats and bullish technical signals. Revenue surged 52% year-over-year in Q2 2026 to $7.38 billion, while net income reached a record $513 million. The stock faces valuation concerns with a P/E of 38.1 and EV/EBITDA of 575.03, but positive cash flow trends and analyst consensus support growth prospects.
The outlook remains optimistic due to robust unit growth and AI-driven cost efficiencies, though risks include profit margin compression and high debt levels. With a consensus price target of $87.18, upside potential exists if execution continues, but investors should monitor competitive pressures and macroeconomic headwinds.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Carvana Co
Carvana Co is an e-commerce platform for buying and selling used cars. The company derives revenue from used vehicle sales, wholesale vehicle sales and other sales and revenues. The other sales and revenues include sales of loans originated and sold in securitization transactions or to financing partners, commissions received on VSCs and sales of GAP waiver coverage.
Read more on CVNA →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
